Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases

European Journal of Nuclear Medicine

Volumn 27, Issue 2, 2000, Pages 123-130

  Palmedo, Holger ^a   Guhlke, Stefan ^a   Bender, Hans ^a   Sartor, Johannes ^a   Schoeneich, Georg ^c   Risse, Jörn ^a   Grünwald, Frank ^a   Russ Knapp Jr , F F ^b   Biersack, Hans Jürgen ^a  

^a UNIVERSITY OF BONN   (Germany)

^b OAK RIDGE NATIONAL LABORATORY   (United States)

^c NONE

Author keywords

188 hydroxyethylidene diphosphonate; Dose escalation; Haematotoxicity; Painful bone metastases; Prostate cancer; Rhenium

Indexed keywords

CREATININE; ETIDRONIC ACID TC 99M; RHENIUM 188;

ARTICLE; BLOOD TOXICITY; BONE METASTASIS; CANCER PAIN; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; DOSE TIME EFFECT RELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MAXIMUM ALLOWABLE CONCENTRATION; PROSTATE CANCER; RADIATION DOSE; RADIOISOTOPE DISTRIBUTION;

EID: 0033953036     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050017     Document Type: Article

References (20)

1. 1. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 Lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16: 1574-1581.
2. 2. Quilty PM, Kirk D, Bolger JJ, et al. A comparison of palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31: 33-40.
3. 3. Porter AT, McEwan AJB, Powe JE, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25: 805-813.
4. 4. Maxon HR, Schroder LE, Hertzberg VS, et al. Rhenium-186(Sn)-HEDP for treatment of painful osseous metastases: results of a double blind crossover comparison with placebo. J Nucl Med 1991; 32: 1877-1881.
5. 5. Quirijnen JMSP, Han SH, Zonnenberg BA, et al. Efficacy of rhenium-186-HEDP in prostate cancer patients with metastatic bone pain. J Nucl Med 1996; 37: 1511-1515.
6. 6. Palmedo H, Bender H, Schomburg A, et al. Therapy with rhenium-186 HEDP in painful bone metastases. Nuklearmedizin 1996; 35: 63-67.
7. 7. Schoeneich G, Palmedo H, Dierke-Dzierzon C, et al. Rhenium-186-HEDP: palliative radionuclide therapy of painful bone metastases. Scand J Urol Nephrol 1997; 31: 445-448.
8. 8. Knapp FF, Beets AL, Guhlke S, et al. Availability of rhenium-188 from alumina-based tungsten-188/rhenium-188 generator for preparation of rhenium-188-labeled radiopharmaceuticals for cancer treatment Anticancer Res 1997; 17: 1783-1796.
9. 9. Maxon HR, Schroder LE. Washburn LC, et al. Rhenium-188 (Sn)-HEDP for treatment of osseous metastases. J Nucl Med 1998; 39: 659-663.
10. 10. Knapp FF, Mirzadeh S, Beets AL, et al. Reactor-produced radioisotopes from ORNL for bone pain palliation. Appl Radiat Isot 1998; 49: 309-315.
11. 186Re-HEDP. Inorganic Chem 1997; 36: 3055-3063.
12. 188Re-HEDP for palliative therapy of bone metastases: preparation, radiochemistry and in-vivo quality control in mice and rats [abstract]. Nuklearmedizin 1996; 36: 34.
13. 188Re-perrhenate or Tc-99m-pertechnetate eluates from tungsten-188/rhenium-188 generators or (n,γ) produced molybdenum-99/technetium-99 m generators to high specific volumes. J Label Compds 1997; 40: 624-626.
14. 14. Miller AB, Hoogstraten B, Staguet M, et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
15. 15. Blake GM, Zivanovic MA, McEwan AJ, et al. Strontium-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 1986; 12: 447-454.
16. 16. Donaldson G. A new approach to calculating pain measurements for cancer patients. Sci Comput Automat 1992; 1: 45-48.
17. 17. Foley KM. The treatment of cancer pain. N Engl J Med 1985; 313: 84-95.
18. 18. De Klerk JMH, Van Het Schip AD, Zonnenberg BA, et al. Evaluation of thrombocytopenia in patients treated with rhenium-186 HEDP: guidelines for individual dose recommendations. J Nucl Med 1994; 35: 1423-1428.
19. 19. De Klerk JMH., Zonnenberg BA., Van Het Schip AD, et al. Dose escalation study of rhenium-186-HEDP in patients with metastatic prostate cancer. Eur J Nucl Med 1994; 21: 1114-1120.
20. 20. De Klerk JMH, Zonnenberg BA., Krouwer HGJ, et al. Transient cranial neuropathy in prostatic cancer with bone metastases after rhenium-186-HEDP treatment. J Nucl Med 1996; 37: 465-467.